$IDRA Recent News Pfizer, Affymetrix weigh on dr
Post# of 94265
Posted On: 12/11/2013 1:38:17 PM
$IDRA Recent News
Pfizer, Affymetrix weigh on drug stocks 2:04 p.m. July 7, 2011 - Val Brickates Kennedy
Idera tumbles 14% on drug setback 1:52 p.m. July 7, 2011 - Val Brickates Kennedy
Tuesday's biggest gaining and declining stocks 4:37 p.m. Jan. 19, 2010 - MarketWatch
Incyte, Idera move on Novartis deals 2:02 p.m. Nov. 25, 2009 - Val Brickates Kennedy
Novartis terminates pact with Idera 8:28 a.m. Nov. 25, 2009 - Val Brickates Kennedy
Wednesday's biggest gaining and declining stocks 4:29 p.m. Dec. 26, 2007 - MarketWatch
Idera Pharmaceuticals' president, Karr, resigns 9:08 a.m. Dec. 26, 2007 - Robert Daniel
Idera Pharma President Karr resigns, stays on board 9:03 a.m. Dec. 26, 2007 - Robert Daniel
Idera signs agonist licensing, collaboration with Merck KGaA 7:10 a.m. Dec. 19, 2007 - Sarah Turner
Idera to get up to $381 mln in milestones 7:03 a.m. Dec. 19, 2007 - Steve Goldstein
Idera, Merck KGaA agree collaboration deal 7:02 a.m. Dec. 19, 2007 - Steve Goldstein
Wednesday's biggest stock gainers and decliners 6:03 p.m. Feb. 28, 2007 - Michael Baron
Idera Pharma started at buy at Merriman Curhan Ford 8:54 a.m. Feb. 7, 2007 - Tomi Kilgore
Drug stocks slip; Nuvelo, Neopharm shares plunge on trial results 4:37 p.m. Dec. 11, 2006 - Carolyn Pritchard
9 Biotechnology Stocks to Buy Now 6:00 a.m. Today - InvestorPlace.com
10-Q: IDERA PHARMACEUTICALS, INC. 7:02 a.m. Nov. 14, 2013 - Edgar Online - (EDG = 10Q, 10K)
Biotech-Focused Baker Bros. Accumulates These 3 Stocks 8:55 a.m. Oct. 1, 2013 - Seeking Alpha
Idera Phase 2 Data Provides For Exciting Q4 2013 And Q1 2014 8:02 a.m. Sept. 25, 2013 - Seeking Alpha
Analysts: Blackstone Mortgage Gaining Traction and 3 Other Research Notes to Browse 1:37 p.m. Aug. 29, 2013 - Wall St. Cheat Sheet
Idera Enters Agreement with NCI to Evaluate Use of TLR Antagonists for Treatment of Genetically Defined Lymphomas 6:39 a.m. Aug. 29, 2013 - benzinga.com
Idera Announces Issuance of US Patent Covering IMO-8400, Lead Candidate in Phase 2 Trial 6:05 a.m. July 18, 2013 - benzinga.com
Idera Pharma to Issue Positive Phase I Trial Results on TLR Antagonist IMO-8400 5:31 a.m. June 21, 2013 - benzinga.com
Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis 6:07 a.m. June 5, 2013 - benzinga.com
10-Q: IDERA PHARMACEUTICALS, INC. 6:49 a.m. May 15, 2013 - Edgar Online - (EDG = 10Q, 10K)
Idera Pharmaceuticals Announces Closing of Common Share Offering 2:19 p.m. May 7, 2013 - benzinga.com
Idera Pharmaceuticals Prices 17.5M Share Offering at $0.50/Share 3:59 a.m. May 2, 2013 - benzinga.com
1 Stock to Buy, 1 Stock to Short: Penny Stocks 8:52 a.m. April 16, 2013 - InvestorPlace.com
Idera Phase 2 of IMO-8400 Receives Clearance from Netherlands Competent Group 6:18 a.m. April 1, 2013 - benzinga.com
10-K: IDERA PHARMACEUTICALS, INC. 6:28 a.m. March 11, 2013 - Edgar Online - (EDG = 10Q, 10K)
UPDATE: Piper Jaffray Initiates Idera Pharmaceuticals at Overweight on Encouraging Data 11:49 a.m. Jan. 3, 2013 - benzinga.com
3 Biotech Stocks To Consider In The Wake Of Recent Developments 1:51 p.m. Dec. 19, 2012 - Seeking Alpha
4 Reasons Why Merck Could Be The Perfect Stock For Dividend Investors 12:11 p.m. Nov. 30, 2012 - Seeking Alpha
Medical Advances May Help Improve Psoriasis Outcomes 5:18 a.m. Nov. 11, 2012 - Seeking Alpha
Amgen Psoriasis Candidate Impresses - Analyst Blog 4:51 p.m. April 4, 2012 - Zacks.com
Senior Appointments, Stock Splits, New Guidelines, Positive Results, and Clinical Trial Updates - Research Report on Receptos, MEDNAX, CombiMatrix, Anacor, and Idera 8:00 a.m. Dec. 10, 2013 - PR Newswire
Idera Pharmaceuticals Opens Enrollment for Phase 1/2 Clinical Trial of IMO-8400 in Waldenstrom's Macroglobulinemia 7:30 a.m. Dec. 4, 2013 - BusinessWire
Idera Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference 4:02 p.m. Nov. 25, 2013 - BusinessWire
Idera Pharmaceuticals Reports Third Quarter 2013 Financial Results and Provides Corporate Update 7:45 a.m. Nov. 14, 2013 - BusinessWire
Idera Pharmaceuticals to Host Conference Call to Report Third Quarter 2013 Financial Results on Thursday, November 14, 2013 4:10 p.m. Nov. 7, 2013 - BusinessWire
Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants 3:14 p.m. Sept. 30, 2013 - BusinessWire
Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants 8:09 a.m. Sept. 25, 2013 - BusinessWire
Idera Pharmaceuticals Announces Public Offering of Common Stock and Pre-Funded Warrants 3:01 p.m. Sept. 24, 2013 - BusinessWire
Five Star Equities Issues New Research Reports on EZCH, IDRA, PSTI and UNFI 8:01 a.m. Sept. 13, 2013 - ACCESSWIRE
Idera to Provide Update on Programs at Stifel Nicolaus Healthcare Conference 11:00 a.m. Sept. 12, 2013 - BusinessWire
Idera to Present at the Stifel Nicolaus 2013 Healthcare Conference 8:25 a.m. Sept. 10, 2013 - BusinessWire
Idera Pharmaceuticals Enters into Agreement with NCI to Evaluate Use of TLR Antagonists for the Treatment of Genetically Defined Lymphomas 7:30 a.m. Aug. 29, 2013 - BusinessWire
Idera Pharmaceuticals Reports Second Quarter 2013 Financial Results and Corporate Highlights 7:00 a.m. Aug. 15, 2013 - BusinessWire
Idera Announces Issuance of US Patent Covering IMO-8400, Lead Candidate in Phase 2 Trial 7:00 a.m. July 18, 2013 - BusinessWire
Idera Pharmaceuticals Appoints James Geraghty as Chairman of the Board of Directors 8:00 a.m. July 10, 2013 - BusinessWire
Idera Pharmaceuticals Announces Results of Phase 1 Clinical Trial of IMO-8400, Toll-like Receptor Antagonist Drug Candidate for Autoimmune and Inflammatory Diseases 7:00 a.m. July 1, 2013 - BusinessWire
Idera Pharmaceuticals to Present Positive Phase 1 Trial Results on TLR Antagonist IMO-8400 for the Treatment of Autoimmune Diseases at FOCIS 2013 6:30 a.m. June 21, 2013 - BusinessWire
Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis 7:00 a.m. June 5, 2013 - BusinessWire
Idera Pharmaceuticals Reports First Quarter 2013 Financial Results 7:15 a.m. May 15, 2013 - BusinessWire
Idera Announces Presentation of Positive Data from Phase 2 Trial of TLR 7 and 9 Antagonist in Patients with Moderate-to-Severe Plaque Psoriasis 6:15 a.m. May 8, 2013 - BusinessWire
Pfizer, Affymetrix weigh on drug stocks 2:04 p.m. July 7, 2011 - Val Brickates Kennedy
Idera tumbles 14% on drug setback 1:52 p.m. July 7, 2011 - Val Brickates Kennedy
Tuesday's biggest gaining and declining stocks 4:37 p.m. Jan. 19, 2010 - MarketWatch
Incyte, Idera move on Novartis deals 2:02 p.m. Nov. 25, 2009 - Val Brickates Kennedy
Novartis terminates pact with Idera 8:28 a.m. Nov. 25, 2009 - Val Brickates Kennedy
Wednesday's biggest gaining and declining stocks 4:29 p.m. Dec. 26, 2007 - MarketWatch
Idera Pharmaceuticals' president, Karr, resigns 9:08 a.m. Dec. 26, 2007 - Robert Daniel
Idera Pharma President Karr resigns, stays on board 9:03 a.m. Dec. 26, 2007 - Robert Daniel
Idera signs agonist licensing, collaboration with Merck KGaA 7:10 a.m. Dec. 19, 2007 - Sarah Turner
Idera to get up to $381 mln in milestones 7:03 a.m. Dec. 19, 2007 - Steve Goldstein
Idera, Merck KGaA agree collaboration deal 7:02 a.m. Dec. 19, 2007 - Steve Goldstein
Wednesday's biggest stock gainers and decliners 6:03 p.m. Feb. 28, 2007 - Michael Baron
Idera Pharma started at buy at Merriman Curhan Ford 8:54 a.m. Feb. 7, 2007 - Tomi Kilgore
Drug stocks slip; Nuvelo, Neopharm shares plunge on trial results 4:37 p.m. Dec. 11, 2006 - Carolyn Pritchard
9 Biotechnology Stocks to Buy Now 6:00 a.m. Today - InvestorPlace.com
10-Q: IDERA PHARMACEUTICALS, INC. 7:02 a.m. Nov. 14, 2013 - Edgar Online - (EDG = 10Q, 10K)
Biotech-Focused Baker Bros. Accumulates These 3 Stocks 8:55 a.m. Oct. 1, 2013 - Seeking Alpha
Idera Phase 2 Data Provides For Exciting Q4 2013 And Q1 2014 8:02 a.m. Sept. 25, 2013 - Seeking Alpha
Analysts: Blackstone Mortgage Gaining Traction and 3 Other Research Notes to Browse 1:37 p.m. Aug. 29, 2013 - Wall St. Cheat Sheet
Idera Enters Agreement with NCI to Evaluate Use of TLR Antagonists for Treatment of Genetically Defined Lymphomas 6:39 a.m. Aug. 29, 2013 - benzinga.com
Idera Announces Issuance of US Patent Covering IMO-8400, Lead Candidate in Phase 2 Trial 6:05 a.m. July 18, 2013 - benzinga.com
Idera Pharma to Issue Positive Phase I Trial Results on TLR Antagonist IMO-8400 5:31 a.m. June 21, 2013 - benzinga.com
Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis 6:07 a.m. June 5, 2013 - benzinga.com
10-Q: IDERA PHARMACEUTICALS, INC. 6:49 a.m. May 15, 2013 - Edgar Online - (EDG = 10Q, 10K)
Idera Pharmaceuticals Announces Closing of Common Share Offering 2:19 p.m. May 7, 2013 - benzinga.com
Idera Pharmaceuticals Prices 17.5M Share Offering at $0.50/Share 3:59 a.m. May 2, 2013 - benzinga.com
1 Stock to Buy, 1 Stock to Short: Penny Stocks 8:52 a.m. April 16, 2013 - InvestorPlace.com
Idera Phase 2 of IMO-8400 Receives Clearance from Netherlands Competent Group 6:18 a.m. April 1, 2013 - benzinga.com
10-K: IDERA PHARMACEUTICALS, INC. 6:28 a.m. March 11, 2013 - Edgar Online - (EDG = 10Q, 10K)
UPDATE: Piper Jaffray Initiates Idera Pharmaceuticals at Overweight on Encouraging Data 11:49 a.m. Jan. 3, 2013 - benzinga.com
3 Biotech Stocks To Consider In The Wake Of Recent Developments 1:51 p.m. Dec. 19, 2012 - Seeking Alpha
4 Reasons Why Merck Could Be The Perfect Stock For Dividend Investors 12:11 p.m. Nov. 30, 2012 - Seeking Alpha
Medical Advances May Help Improve Psoriasis Outcomes 5:18 a.m. Nov. 11, 2012 - Seeking Alpha
Amgen Psoriasis Candidate Impresses - Analyst Blog 4:51 p.m. April 4, 2012 - Zacks.com
Senior Appointments, Stock Splits, New Guidelines, Positive Results, and Clinical Trial Updates - Research Report on Receptos, MEDNAX, CombiMatrix, Anacor, and Idera 8:00 a.m. Dec. 10, 2013 - PR Newswire
Idera Pharmaceuticals Opens Enrollment for Phase 1/2 Clinical Trial of IMO-8400 in Waldenstrom's Macroglobulinemia 7:30 a.m. Dec. 4, 2013 - BusinessWire
Idera Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference 4:02 p.m. Nov. 25, 2013 - BusinessWire
Idera Pharmaceuticals Reports Third Quarter 2013 Financial Results and Provides Corporate Update 7:45 a.m. Nov. 14, 2013 - BusinessWire
Idera Pharmaceuticals to Host Conference Call to Report Third Quarter 2013 Financial Results on Thursday, November 14, 2013 4:10 p.m. Nov. 7, 2013 - BusinessWire
Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants 3:14 p.m. Sept. 30, 2013 - BusinessWire
Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants 8:09 a.m. Sept. 25, 2013 - BusinessWire
Idera Pharmaceuticals Announces Public Offering of Common Stock and Pre-Funded Warrants 3:01 p.m. Sept. 24, 2013 - BusinessWire
Five Star Equities Issues New Research Reports on EZCH, IDRA, PSTI and UNFI 8:01 a.m. Sept. 13, 2013 - ACCESSWIRE
Idera to Provide Update on Programs at Stifel Nicolaus Healthcare Conference 11:00 a.m. Sept. 12, 2013 - BusinessWire
Idera to Present at the Stifel Nicolaus 2013 Healthcare Conference 8:25 a.m. Sept. 10, 2013 - BusinessWire
Idera Pharmaceuticals Enters into Agreement with NCI to Evaluate Use of TLR Antagonists for the Treatment of Genetically Defined Lymphomas 7:30 a.m. Aug. 29, 2013 - BusinessWire
Idera Pharmaceuticals Reports Second Quarter 2013 Financial Results and Corporate Highlights 7:00 a.m. Aug. 15, 2013 - BusinessWire
Idera Announces Issuance of US Patent Covering IMO-8400, Lead Candidate in Phase 2 Trial 7:00 a.m. July 18, 2013 - BusinessWire
Idera Pharmaceuticals Appoints James Geraghty as Chairman of the Board of Directors 8:00 a.m. July 10, 2013 - BusinessWire
Idera Pharmaceuticals Announces Results of Phase 1 Clinical Trial of IMO-8400, Toll-like Receptor Antagonist Drug Candidate for Autoimmune and Inflammatory Diseases 7:00 a.m. July 1, 2013 - BusinessWire
Idera Pharmaceuticals to Present Positive Phase 1 Trial Results on TLR Antagonist IMO-8400 for the Treatment of Autoimmune Diseases at FOCIS 2013 6:30 a.m. June 21, 2013 - BusinessWire
Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis 7:00 a.m. June 5, 2013 - BusinessWire
Idera Pharmaceuticals Reports First Quarter 2013 Financial Results 7:15 a.m. May 15, 2013 - BusinessWire
Idera Announces Presentation of Positive Data from Phase 2 Trial of TLR 7 and 9 Antagonist in Patients with Moderate-to-Severe Plaque Psoriasis 6:15 a.m. May 8, 2013 - BusinessWire
(0)
(0)